Why the study?
Achieving a definite etiological diagnosis in patients with hypertrophic cardiomyopathy is challenging due to the need to exclude mimicking conditions such as genocopies or phenocopies.
This case highlights the importance of genetic testing for definitive etiological diagnosis in patients with hypertrophic cardiomyopathy, as compound heterozygous mutations can occur.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for dual mutations in HCM overlap syndromes; leaves open need for broader panels before diagnostic change.
In this report, an atypical case of Noonan syndrome (NS) associated with sarcomeric hypertrophic cardiomyopathy (HCM) in a 33-year-old patient was described. Genetic testing revealed two different disease-causing mutations: a mutation in the PTPN11 gene, explaining NS, and a mutation in the MYBPC3 gene, known to be associated with HCM. This case exemplifies the challenge in achieving a definite etiological diagnosis in patients with HCM and the need to exclude other diseases mimicking this condition (genocopies or phenocopies). Compound heterozygous mutations are rare but possible in HCM patients. In conclusion, this study highlights the important role of genetic testing as a necessary diagnostic tool for performing a definitive etiological diagnosis of HCM.
No takes yet. Share an insight, caveat, or question.
Caiazza et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: